Nephrotoxicity from chemotherapy: prevention and management
Vogelzang, N.J.
Oncology 5(10): 97
1991
ISSN/ISBN: 0890-9091 PMID: 1838278 Document Number: 4368
Among the most devastating effects of antineoplastic chemotherapy is nephrotoxicity. This article discusses the effects of plicamycin, methotrexate, mitomycin C, nitrosoureas, 5-azacytidine, cisplatin, ifosfamide, carboplatin, and gallium nitrate on kidney function when these drugs are used either alone or in combination with each other and/or other agents. The importance of adequate hydration during chemotherapy in preventing and reversing drug-induced nephrotoxicity is also discussed.
Document emailed within 1 workday
Related Documents
Makowka, L.; Lopatin, W.; Gilas, T.; Falk, J.; Phillips, M.J.; Falk, R. 1986: Prevention of cyclosporine (CyA) nephrotoxicity by synthetic prostaglandins Clinical Nephrology 25 Suppl. 1: S89-S94Izumi, T. 1988: Experimental studies on the nephrotoxicity of cisplatin--amelioration of nephrotoxicity by continuous infusion Hinyokika Kiyo. Acta Urologica Japonica 34(1): 37-45
Kojima, R.; Suzuki, Y. 1984: Studies on the nephrotoxicity of aminoglycoside antibiotics and protection from these effects. (2). Protective effect of latamoxef against gentamicin nephrotoxicity Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 84(5): 463-469
Smeesters, C.; Chaland, P.; Giroux, L.; Moutquin, J.M.; Etienne, P.; Douglas, F.; Corman, J.; St-Louis, G.; Daloze, P. 1988: Prevention of acute cyclosporine A nephrotoxicity by a thromboxane synthetase inhibitor Transplantation Proceedings 20(2 Suppl. 2): 663-669
Yano, T. 2013: Cellular and molecular mechanisms in drug-induced nephrotoxicity and its prevention Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 142(4): 172-177
Bennett, W.M. 1994: Clinical algorithms for cyclosporine management based on pathophysiologic constructs of nephrotoxicity Transplantation Proceedings 26(5): 2583-2584
Fabre, J.; de Sousa, R. 1980: Aminoglycoside nephrotoxicity. II. Transtubular transport and factors modifying aminoglycoside nephrotoxicity Nephrologie 1(2): 89-94
Kurita, A.; Takashima, S.; Nakata, M.; Kubo, Y.; Saiki, T.; Ohsumi, S.; Yokoyama, N.; Tanada, M.; Takiyama, W.; Saeki, H. 1997: Granisetron versus granisetron plus methylprednisolone in the prevention of chemotherapy induced nausea and vomiting--in adjuvant chemotherapy, including CDDP against gastric cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 24(1): 49-54
Davis, M.Miller.; Jones, D.W. 2002: The role of lifestyle management in the overall treatment plan for prevention and management of hypertension Seminars in Nephrology 22(1): 35-43
Rodríguez, Fátima.; Lamelo, A.; Arnal, F.; Remón, C.; Villanueva, R.; Vázquez, G. 2010: Development of an alarm management system to manage those alarms occurred during the illness prevention and management inside and outside the hospital environment Studies in Health Technology and Informatics 156: 57-64
Belleau, F.P. 1987: Chemotherapy: prevention of alopecia Nursing Quebec 7(5): 20-23
Wagner, W.H. 1986: Malaria prevention. Chemotherapy and immune prophylaxis. 3. Immune response of infected organism. Perspectives of Malaria prevention Arzneimittel-Forschung 36(3): 409-415
Jones, J.A. 1995: Root caries: prevention and chemotherapy American Journal of Dentistry 8(6): 352-357
Bregetzer, J. 1978: The management of cancer chemotherapy Revue de l'Infirmiere 28(1): 5-7
Sandoe, J.A.T.; Barlow, G.; Chambers, J.B.; Gammage, M.; Guleri, A.; Howard, P.; Olson, E.; Perry, J.D.; Prendergast, B.D.; Spry, M.J.; Steeds, R.P.; Tayebjee, M.H.; Watkin, R. 2015: Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint Working Party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British Heart Rhythm Society (BHRS), British Cardiovascular Society (BCS), British Heart Valve Society (BHVS) and British Society for Echocardiography (BSE) Journal of antimicrobial chemotherapy 70(2): 325-359
Lutsep, H.L. 2007: New developments in secondary stroke prevention: impact of the European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) on clinical management Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association 16(6): 263-267
Villavicencio, H. 1991: Prevention of azoospermia in patients treated with chemotherapy and/or radiotherapy Medicina Clinica 97(10): 386-387
Tsukuda, M. 2002: Prevention and treatment for adverse events induced by chemotherapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 29(7): 1284-1291
Münzberg, S. 2009: Prevention of chemotherapy-induced oral mucositis: what really helps Pflege Zeitschrift 62(11): 671-673
Sotoyama, E.; Sugihara, S.; Kaneko, T.; Egami, T.; Taguchi, I.; Seguchi, M.; Kato, A.; Hirakawa, S.; Tateno, J.; Tsukahara, K.; Okita, K. 2005: Management of ambulatory chemotherapy in a hospital Gan to Kagaku Ryoho. Cancer and ChemoTherapy 32(10): 1496-1497